๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the register
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase IV
Evaluating the clinical effectiveness of sodium bicarbonate for critically ill patients with metabolic acidosis and acute kidney injury
2025-523914-10-00Critical illness, Acute kidney injury, Metabolic acidosis
Universitaet Muenster
Nutritional and Metabolic Diseases
Germany
17/03/2026
Phase I
A Phase 1, open label, randomised, 2-period, 2 sequence, 7-days repeat-dosing, crossover oral pharmacokinetic trial comparing multiple dosing of CS014 to valproic acid in healthy adults.
2025-524883-39-00Cardiopulmonary diseases with contributions of thrombosis, โ€ฆ
Cereno Scientific AB
Cardiovascular Diseases
Sweden
17/03/2026
Phase II
SHIELD โ€“ Swift Hydrocortisone Intervention after trauma exposure
2025-523350-13-02Posttraumatic Stress Disorder (PTSD)
Amsterdam UMC Stichting
Mental Disorders
Netherlands
17/03/2026
Phase I/II
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00progressive/relapsed/refractory pediatric low-grade glioma โ€ฆ
Universitaetsklinikum Heidelberg AรถR
Nervous System Diseases
Denmark, Czechia, Austria, Sweden, Germany
17/03/2026
Phase III
AchilleS tendinoPathy treated with cortIcosteRoid injEctions.
2025-524057-13-00Achilles tendinopathy
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Musculoskeletal Diseases
Netherlands
16/03/2026
Phase III
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
2025-522878-36-00Chronic Spontaneous Urticaria
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults
2025-522782-30-00CCI
UCB Biopharma
Immune System Diseases
Croatia, Poland, Germany, Czechia, Slovakia, Bulgaria
16/03/2026
Phase II
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
2024-511656-41-00Duchenne Muscular Dystrophy
Biomarin Pharmaceutical Inc.
Musculoskeletal Diseases
Spain, Italy, Netherlands
16/03/2026
Phase II
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
2025-523600-68-00Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Curis Inc.
Neoplasms
Spain, Italy
16/03/2026
Phase I
Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer: a phase I study
2025-522864-34-00Gastric cancer
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
16/03/2026
Phase I
A Phase 1, drug-drug interaction trial of IMU-838 with oral contraceptives in women
2026-525208-90-00Multiple sclerosis
Immunic AG
Nervous System Diseases
Belgium
16/03/2026
Phase IV
The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglycemia in People with Type 1 Diabetes
2025-523996-45-00Type 1 Diabetes Mellitus
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
16/03/2026
Phase I
Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.
2025-522627-10-00No medical condition.
Laboratorios Cinfa S.A.
Not possible to specify
Portugal
13/03/2026
Phase II
Comparison of esketamine mouthwash versus intravenous administration for the treatment of chemotherapy/radiotherapy-induced mucositis
2025-522545-22-00Oral mucositis
Amsterdam UMC Stichting
Anesthesia and Analgesia
Netherlands
13/03/2026
Phase III
Prestige 2- RimegePant in RElation to obeSiTy in miGainE
2025-521475-31-00Migraine
Konvent Der Barmherzigen Brueder
Nervous System Diseases
Austria
13/03/2026
Phase I
A study to test how different doses of BI 3814916 are tolerated by healthy people
2025-523262-25-00healthy volunteer trial
Boehringer Ingelheim International GmbH
Not possible to specify
Belgium
13/03/2026
Phase II
A Phase 2, monocentric, prospective, nonrandomized, open-label, experimental study to evaluate efficacy and safety of intrabronchial instillation of liposomal Amphotericin B in patients with simple pulmonary aspergilloma.
2025-523501-15-00Simple aspergilloma
Pauls Stradins Clinical University Hospital
Respiratory Tract Diseases
Latvia
13/03/2026
Phase IV
The effect of Broncho-Vaxom on the COPD exacerbations in terms of lung function, lung mechanics, immune state, body composition, quality of life and physical activity.
2025-524501-32-02COPD exacerbation
Semmelweis University, University Of Pecs
Respiratory Tract Diseases
Hungary
13/03/2026
Phase I
Study in healthy volunteers to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as a single intravenous injection as well as safety, tolerability and the effects on certain blood values.
2025-522244-40-00It is used to treat symptomatic anaemia in chronic renal faโ€ฆ
Blau Farmaceutica S.A.
Hemic and Lymphatic Diseases
Germany
13/03/2026
Phase I
Phase 1 open label trial of MST-0312 alone and in combination in subjects with solid malignancies
2025-524446-10-00Solid Malignancies
Mestag Therapeutics Limited
Neoplasms
Spain
13/03/2026
Phase IV
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis
Care Arthritis Ltd.
Eye Diseases
Spain, Poland, Netherlands, France, Bulgaria, Germany
13/03/2026
Phase I
A research study looking at how NNC0487-0111 affects food intake, appetite and metabolism after meals in people with obesity
2025-521393-34-00Participants with obesity, but otherwise healthy
Novo Nordisk A/S
Not possible to specify
Germany
13/03/2026
Phase IV
GASPS Study: General Anaesthesia vs Spinal anaesthesia: Patient outcomes and Success in Outpatient primary total knee and hip Arthroplasty
2024-520127-89-00Total knee and hip arthroplasties
Region Oerebro Laen
Surgical Procedures, Operative
Sweden
12/03/2026
Phase III
โ€œIntravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trialโ€ THE IVT ALL IN TRIAL
2024-520414-21-00Adult patients with a LVOS with large core within 9 hours oโ€ฆ
Assistance Publique Hopitaux De Paris
Nervous System Diseases
France
12/03/2026
Phase I/II
IL-1ฮฒ blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)
2025-524834-24-00diabetic patients pancreatic transplant
Centre Hospitalier Universitaire De Nantes
Immune System Diseases
France
12/03/2026
Phase II
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)
2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands
12/03/2026
Phase I
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study
2024-512515-45-01Non-Small Cell Lung Cancer
Theras Inc.
Neoplasms
Spain, Denmark
12/03/2026
Phase III
An open label, pharmacokinetic and safety study of Combogesicยฎ IV in pediatric patients with acute pain.
2025-524431-39-00Acute pain
Aft Pharmaceuticals Limited
Anesthesia and Analgesia
Hungary
12/03/2026
Phase II
A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusion weighted imaging on MRI after treatment with intravenous tocilizumab or placebo in patients above 18 years of age with acute ischemic stroke undergoing endovascular thrombectomy.
2025-521269-28-00Acute ischemic stroke
Oslo University Hospital HF
Nervous System Diseases
Norway, Denmark
12/03/2026
Phase I
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors
2025-523553-34-00Advanced and Metastatic Solid tumors
BeOne Medicines I GmbH
Neoplasms
Italy, Spain
12/03/2026
Phase I
A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation
2025-521062-10-00KRAS G12D Mutated Advanced Solid Tumors
Arvinas Operations Inc.
Neoplasms
Spain, Italy
12/03/2026
Phase I
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
2024-517943-29-00Pulmonary Hypertension associated with interstitial lung diโ€ฆ
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase I
A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity
2025-524856-73-00Not Applicable
F. Hoffmann-La Roche AG
Population Characteristics
Netherlands
11/03/2026
Phase II
INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS
2024-515009-24-00High grade malignant brain neoplasm
Clinica Universidad De Navarra
Nervous System Diseases
Netherlands, Spain
11/03/2026
Phase III
TENACITY โ€“ A Phase III, prospective, randomized, open-label, blinded endpoint assessment (PROBE) to assess efficacy and safety of i.v. tenecteplase vs standard of care in patients with acute ischemic stroke (including wake-up stroke), last known well >4.5 h with imaging evidence of salvageable ischemic tissue
2025-522542-40-00Acute Ischemic Stroke
Boehringer Ingelheim International GmbH
Cardiovascular Diseases
Greece, Norway, Hungary, Romania, Spain, Bulgaria
11/03/2026
Phase I
A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 mg Tablet in Healthy Adults Under Fed Conditions
2026-525342-29-00Transthyretin amyloidosis
Pfizer Inc.
Pathological Conditions, Signs and Symptoms
Belgium
11/03/2026
Phase II
Ultimate dePletion of autoReactive b cells using Obinutuzumab from sjร–gren's syndrome affected Tissues study- UPROOT study
2024-519884-16-00Sjรถgren's syndrome
Radboud universitair medisch centrum Stichting
Immune System Diseases
Netherlands
11/03/2026
Phase II
B7981119 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa
2025-522705-37-00HIDRADENITIS SUPPURATIVA
Pfizer Inc.
Skin and Connective Tissue Diseases
Germany, Poland, Spain, Greece
11/03/2026
Phase I
Bioequivalence Study of Empagliflozin
2026-525434-33-00Not applicable (submitted trial is a BE study in healthy paโ€ฆ
Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Nutritional and Metabolic Diseases
Czechia
11/03/2026
Phase II
A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 ยตg HFA-152a versus CHF5993 pMDI 100/6/12.5 ยตg HFA-134a in subjects with mild to moderate asthma. [TRECONY]
2025-521456-35-00Mild to moderate asthma
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Slovakia, Czechia, Romania, Latvia, Germany, Hungary, Bulgaria, Poland
11/03/2026
Phase III
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
2025-522484-15-00ER+/HER2- early breast cancer
WSG Women's Cancer Study Group GmbH
Neoplasms
Germany, Spain, Austria
11/03/2026
Phase III
Prehospital pulse-dose glucocorticoid in patients with STEMI โ€“ the PULSE-MI 2 trial
2025-524320-21-00ST-segment Elevation Myocardial Infarction
Rigshospitalet
Cardiovascular Diseases
Denmark
11/03/2026
Phase I
Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRรŸ) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
2026-525309-11-00Systemic Sclerosis-associated Interstitial Lung Disease (SSโ€ฆ
Antaros Medical AB
Diagnosis
Sweden
11/03/2026
Phase IV
ILHEP : Effect of perioperative Intravenous Lidocaine on postoperative opioid related-side effects after open HEPatectomy: a multicentre prospective randomized controlled study
2025-522462-73-00Postanesthetic complications in patients undergoing open heโ€ฆ
Centre Hospitalier Universitaire De Rennes
Anesthesia and Analgesia
France
10/03/2026
Phase III
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
2025-523263-37-00Previously Untreated Advanced or Metastatic Gastric, Gastroโ€ฆ
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Germany, Spain, Poland, France, Italy, Romania
10/03/2026
Phase III
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
2025-523224-45-00Untreated, Unresectable or Metastatic Colorectal Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
2025-522775-29-00Depressive episodes associated with Bipolar disorder I or Iโ€ฆ
Xenon Pharmaceuticals Inc.
Mental Disorders
Germany, Bulgaria, Spain, Poland
10/03/2026
Phase I/II
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstromโ€™s macroglobulinemia
2025-522295-91-00relapsed or refractory Waldenstromโ€™s macroglobulinemia
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Denmark, Belgium, Netherlands
10/03/2026
Phase I
The clinical trial to study a new drug, AP-2.
2025-524480-21-00ALS and related disorders like frontotemporal dementia and โ€ฆ
Molefy Pharma S.L.
Nervous System Diseases
Spain
10/03/2026
Phase II
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
2024-518013-25-00Idiopathic Pulmonary Fibrosis
AbbVie Deutschland GmbH & Co. KG
Respiratory Tract Diseases
Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania
10/03/2026
Phase II
Upadacitinib in adult patients with erosive mucosal Lichen Planus and Lichen Planopilaris: a prospective multicenter randomized placebo-controlled study. (Upa30-LP)
2025-522870-35-00Lichen
Centre Hospitalier Universitaire De Nice
Skin and Connective Tissue Diseases
France
09/03/2026
Phase III
REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome
2024-519711-33-01Angelman syndrome
Ionis Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Germany, Poland, Spain
09/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
2025-522713-29-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
Belgium, Italy, Spain, Germany, France
09/03/2026
Phase III
Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomised, double-blind, placebo-controlled study _ PROSTASICKLE
2025-522005-38-00sickle cell anaemia with vaso-occlusive crisis
Centre Hospitalier Universitaire Rouen
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
09/03/2026
Phase I/II
Late immunity following single immunization with GA2 sporozoites (GACHA)
2025-524045-27-00Falciparum malaria
Leids Universitair Medisch Centrum (LUMC)
Parasitic Diseases
Netherlands
09/03/2026
Phase III
PaTHway Adolescent - A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Population (12 Years to Less Than 18 Years of Age) with Chronic Hypoparathyroidism
2025-523928-52-00Chronic hypoparathyroidism
Ascendis Pharma Bone Diseases A/S
Hormonal diseases
Germany, France, Romania, Poland
09/03/2026
Phase II
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
2025-522578-35-00Atopic Dermatitis
UCB Biopharma
Skin and Connective Tissue Diseases
Bulgaria, Czechia, Germany, Poland, Hungary
09/03/2026
Phase I
A Phase 1, placebo-controlled, randomized, participant- and assessor-blind, single-center study to assess the safety and immunogenicity of 2 dose levels of Nipah measles vector (MV-NiV) vaccine administered subcutaneously either as a single dose or as 2 consecutive doses at 4-week interval, in healthy non-exposed volunteers, aged 18-40 years
2025-522293-37-00Nipah Virus
Teikyo University
Virus Diseases
Belgium
09/03/2026
Phase I
A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults
2025-524178-40-00Chronic Kidney Disease
Bayer AG
Cardiovascular Diseases
Germany
09/03/2026
Phase I/II
CAT-01
2024-517594-24-01Cervical carcinoma
Karolinska Institutet
Neoplasms
Sweden
09/03/2026
Phase II
SGL-TX-PTDM: SGLT2i effect on PTDM development and kidney allograft function in kidney transplant recipients: A randomized, double-blind, placebo controlled, national multicenter trial
2024-518774-14-00Kidney transplant recipients
Odense University Hospital
Not possible to specify
Denmark
09/03/2026
Phase IV
Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial
2025-524327-53-00Infertility
Region Midtjylland
Not possible to specify
Denmark
09/03/2026
Phase I
Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes
2025-521595-55-00Type 2 Diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
09/03/2026
Phase I/II
Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients
2024-510723-18-00Chronic active antibody mediated rejection
Region Midtjylland
Immune System Diseases
Denmark
09/03/2026
Phase III
CANDISHORT : A randomized study of a short duration therapy for candidemia
2024-514244-81-00Uncomplicated candidemia
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
06/03/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
2025-522831-33-00Hidradenitis Suppurativa
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
France, Poland, Netherlands, Germany
06/03/2026
Phase III
APICALE - Cervical facet injection of corticosteroids for the management of cervicobrachialgia : protocol for a randomized pilot study
2024-511790-30-00Cervicobrachial Neuralgia
Assistance Publique Hopitaux De Paris
Nervous System Diseases
France
06/03/2026
Phase III
A Long-Term Follow-Up Study for Participants Previously Treated with KYV-101 (KYSA-4)
2024-511198-31-00Myasthenia Gravis, Rheumatoid Arthritis, Lupus Nephritis, Sโ€ฆ
Kyverna Therapeutics Inc.
Immune System Diseases
Germany
06/03/2026
Phase I
A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease
2025-524693-42-00Stable Coronary Artery Disease (CAD)
F. Hoffmann-La Roche AG
Cardiovascular Diseases
Netherlands
06/03/2026
Phase III
Doxycycline post-exposure prophylaxis: Weekly versus event-driven Intake for STI prevention among MSM and TGW taking PrEP (Doxy-WISE study)
2025-524823-34-00Sexually Transmitted Infections
Institute Of Tropical Medicine
Bacterial Infections and Mycoses
Belgium
06/03/2026
Phase II
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
2025-521327-67-00Metastatic Castration-Resistant Prostate Cancer
F. Hoffmann-La Roche AG
Neoplasms
Germany, France, Italy, Spain
06/03/2026
Phase I
A Phase I, open-label, non-randomized study to assess the absorption, distribution, metabolism and excretion (ADME) and pharmacokinetics of LTP001 following a single oral dose of [14C]LTP001 in healthy male participants
2025-524172-29-00Healthy volunteers
Novartis Pharma AG
Not possible to specify
Netherlands
06/03/2026
Phase I/II
An Adaptive Dose Escalation and Expansion Basketย Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
2025-523802-34-00Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombโ€ฆ
TargED Biopharmaceuticals B.V.
Hemic and Lymphatic Diseases
Germany, France, Italy, Spain
06/03/2026
Phase II
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohnโ€™s disease or ulcerative colitis
2025-522511-42-00Crohn's disease, Colitis Ulcerative
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase III
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)
2025-522231-34-00Diabetic Macular Edema
Alvotech Swiss AG
Eye Diseases
Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria
06/03/2026
Phase I
A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)
2025-524852-74-00Hypercholesterolaemia
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
06/03/2026
Phase I
Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health
2025-522920-28-00Obesity, CCI, CCI
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark
06/03/2026
Phase I
Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321
2025-524053-14-00Graves Disease
Lycia Therapeutics Inc.
Immune System Diseases
Netherlands
06/03/2026
Phase I
A Study of PHN-012 in Patients With Advanced Solid Tumors
2025-523756-31-00Advanced Solid Tumors
Pheon Therapeutics Limited
Neoplasms
Spain
06/03/2026
Phase I
(21174) Relative bioavailability study to investigate the pharmacokinetics of a single oral dose of asundexian administered as 50 mg pediatric formulation in comparison to 50 mg tablet (adult formulation) in fasted state and to investigate the effect of a high-fat, high-calorie meal on the 50 mg pediatric formulation in healthy adult participants
2025-523677-41-00Prevention of thromboembolic events
Bayer AG
Cardiovascular Diseases
Germany
06/03/2026
Phase III
Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial PALADIN [PeripherAL Arterial DIsease Network] -DAPTCLTI
2025-524297-42-00CLTI defined as Rutherford category 4 or 5
Fondation Hopital Saint Joseph
Cardiovascular Diseases
France
05/03/2026
Phase III
Effect of Empagliflozin in patients with eGFR between 10 and 20 ml/min/1.73m2 - EMPA [10-20]
2025-522119-41-00Patients with renal impairment and type 2 diabetes.
Centre Hospitalier Universitaire De Nice
Therapeutics
France
05/03/2026
Phase III
CUSHMAH - Benefit of steroidogenesis inhibitors in Mild Cushing syndrome (Mild Autonomous Cortisol Secretion): a randomized trial in patients with Primary Bilateral Macronodular Adrenocortical Hyperplasia
2023-507010-27-00Primary Bilateral Macronodular Adrenal Hyperplasia causing โ€ฆ
Assistance Publique Hopitaux De Paris
Nutritional and Metabolic Diseases
France
05/03/2026
Phase I/II
A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in patients with Active Noninfectious Uveitis affecting the Posterior Segment
2025-521713-57-00Noninfectious Uveitis
Regeneron Pharmaceuticals Inc.
Eye Diseases
France
05/03/2026
Phase II
KET01-IIT03: A Pilot, Open-label Phase II Trial of Adjunctive Treatment with Ketamine Hydrochloride Prolonged-Release Tablets (KET01) during the Initiation of Antidepressant Therapy in Major Depressive Disorder
2025-524841-28-00Major Depressive Disorder
Region Skane
Mental Disorders
Sweden
05/03/2026
Phase I/II
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
2025-521859-23-00PSMA-positive mCRPC with prior exposure to at least one priโ€ฆ
Novartis Pharma AG
Neoplasms
Germany, France, Spain, Italy
05/03/2026
Phase I
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
2025-522367-15-00Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endโ€ฆ
Eli Lilly & Co.
Neoplasms
Germany
05/03/2026
Phase IV
Botulinum toxin in open abdomen closure. A multicentric randomized controlled single-blind clinical trial to evaluate the efficacy of early administration of botulinum toxin for primary midline closure in patients with an open abdomen.
2025-522410-23-00open abdomen
Hospital Universitario La Paz
Not possible to specify
Spain
04/03/2026
Phase II
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY โ€“ A Steno MODERN-MODY project (MM-SUUP)
2025-524679-22-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), Mโ€ฆ
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
04/03/2026
Phase IV
Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial
2025-522381-68-00Severe refractory cancer pain
Vrije Universiteit Brussel
Anesthesia and Analgesia
Belgium
04/03/2026
Phase I
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.
2026-525256-29-00Comparative bioavailability study under fasting conditions
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
04/03/2026
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase I
Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).
2025-525076-29-00Phase I study in healthy male volunteers. Intended indicatiโ€ฆ
Nucleus Medical GmbH
Immune system processes
Germany
04/03/2026
Phase II
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.
2025-523037-25-00Patients at high risk for Cardiac Surgery Associated โ€“ Acutโ€ฆ
River 2 Renal Corp.
Pathological Conditions, Signs and Symptoms
Italy, Germany
04/03/2026
Phase I/II
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2024-512248-47-00Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Neoplasms
Italy, Germany, Greece, Poland, Hungary, Spain
04/03/2026
Phase IV
A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
2025-524944-37-00Herpes Zoster
Gentofte Hospital, GlaxoSmithKline Biologicals
Skin and Connective Tissue Diseases
Denmark
04/03/2026
Phase II
Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON
2025-524343-13-00Leber's Hereditary Optic Neuropathy
Centre Hospitalier Universitaire D'Angers
Eye Diseases
France
03/03/2026
Phase I
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
2025-523232-39-00Advanced Solid Tumors
Merck Healthcare KGaA
Neoplasms
Spain
03/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Rows per page Showing 1301–1400 of 2500
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe?page=14

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.